Launch of First US Market Product Vancomycin Hydrochloride for Injection, USP
The product has an estimated market size of $338M for the 12 months ending August 2018 according to officials with IQVIA.
Officials with Xellia Pharmaceuticals (‘Xellia’), announced they have launched Vancomycin Hydrochloride for Injection, USP within the United States market.
In a prepared statement about the approval, Craig Boyd, President of Xellia North America, said: “As a leading global supplier of Vancomycin API, we are excited to now offer Vancomycin 1 g and 10 g in the US from our vertically integrated supply chain and significant injectable manufacturing footprint. This is the first of many key launches that will bring Xellia’s strong portfolio of established and innovative products to patients in need of critical anti-infective treatments.”
Full prescribing information for Vancomycin Hydrochloride for Injection, USP can be found at www.xellia.com/us.
The product has an estimated market size of $338M for the 12 months ending August 2018 according to officials with IQVIA.
